The global hemophilia market is anticipated to grow with a significant CAGR of 6% during the forecast period. The hemophilia market growth is owing to the increasing demand for the prophylactic treatment of hemophilia. In addition to this, the increasing engagement of healthcare professionals, hemophilia treatment centers, as well as hemophilia societies to improve the care of hemophilia patients and their quality of life is also expected to drive the hemophilia market shares. Moreover, the continuous evolving treatment of hemophilia in recent years is also anticipated to propel the growth of the hemophilia market.
Browse the full report description of "Global Hemophilia Market Size, Share & Trends Analysis Report By Type (Hemophilia A, Hemophilia B, and, Others), By Therapy (Replacement Therapy, Gene Therapy, and Others), By Product Type (Recombinant Coagulation Factor Concentrates, Plasma-derived Coagulation Factor Concentrates and Others) Forecast Period (2020-2026)" at https://www.omrglobal.com/industry-reports/hemophilia-market
In general, the treatment of monogenetic bleeding disorders that is hemophilia A and B was done with the systemic protein replacement therapy. However, in recent years, a variety of diverse molecular medicines, ranging from antibody to gene to RNA therapy are transforming the treatment of hemophilia.
Moreover, the traditional replacement therapy used in the treatment of hemophilia required intravenous infusions of the factors for two to three times a week. While the new therapies in the market with extended half-life products are expected to reduce the frequency of injections. Additionally, multiple gene-editing techniques are under clinical or preclinical investigation for the treatment of hemophilia. Therefore, these new therapies and approaches that are being tested or launched are anticipated to considerably drive the size of the hemophilia industry during the forecast period.
In addition to this, several potential drugs can be used for the treatment of hemophilia are in their trials phase. These potential drugs are anticipated to provide new opportunities for the growth of the hemophilia market upon their market launch. For instance, Fitusiran an RNA-interference drug is in its Phase III trials. It is intended to be once a month injection that can both inhibits antithrombins and promotes the production of thrombin. Fitusiran can be used in both hemophilia A as well as hemophilia B treatment. Moreover, in January 2020 Sangamo Therapeutics has handed over the development of SB-525, (a gene therapy for hemophilia A), to Pfizer Inc. The company will now advance the therapy into Phase 3 clinical trials.
Global Hemophilia Market- Segmentation
By Type
By Therapy
By Product Type
Global Hemophilia Market- Segment by Region
North America
Europe
Asia-Pacific
Rest of the World
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/hemophilia-market